Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dara@home trial of home self-administration of daratumumab in relapsed multiple myeloma
ACTRN12624001468516Phase 2Not yet recruiting
- Sponsor
- Australasian Myeloma Research Consortium
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of daratumumab in multiple myeloma (MM), sponsored by Australasian Myeloma Research Consortium. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12624001468516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624001468516.